We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Panel Recommends Onyx Myeloma Drug, Votes Down Sanofi VTE Drug
Panel Recommends Onyx Myeloma Drug, Votes Down Sanofi VTE Drug
June 22, 2012
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 11–0 with one abstention to recommend approval for Onyx Pharmaceuticals’ Kyprolis for patients with relapsed and refractory multiple myeloma who have received at least two prior lines of therapy.